Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given an average rating of “Moderate Buy” by the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $35.8462.

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 target price for the company. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Stifel Nicolaus set a $41.00 price target on Denali Therapeutics in a report on Monday, June 22nd. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $22.28 on Wednesday. Denali Therapeutics has a twelve month low of $12.58 and a twelve month high of $27.30. The firm has a fifty day simple moving average of $24.44 and a 200 day simple moving average of $21.85. The company has a market capitalization of $3.56 billion, a PE ratio of -7.85 and a beta of 1.01. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the business earned ($0.72) earnings per share. On average, sell-side analysts forecast that Denali Therapeutics will post -2.67 EPS for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently made changes to their positions in DNLI. State of Wyoming increased its position in shares of Denali Therapeutics by 24.7% during the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock valued at $44,000 after purchasing an additional 532 shares during the last quarter. Intrust Bank NA increased its holdings in Denali Therapeutics by 5.6% during the fourth quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after buying an additional 589 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Denali Therapeutics by 1.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock worth $860,000 after buying an additional 600 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Denali Therapeutics by 8.7% in the first quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock worth $177,000 after acquiring an additional 739 shares during the period. Finally, Pier 88 Investment Partners LLC raised its position in Denali Therapeutics by 1.1% in the fourth quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after acquiring an additional 760 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.